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http://dx.doi.org/10.1016/j.ccr.2014.02.008SUMMARYChromosomal inversion between 3q21 and 3q26 results in high-risk acute myeloid leukemia (AML). In this
study, we identified a mechanism whereby a GATA2 distal hematopoietic enhancer (G2DHE or 77-kb
enhancer) is brought into close proximity to the EVI1 gene in inv(3)(q21;q26) inversions, leading to leukemo-
genesis.We examined the contribution of G2DHE to leukemogenesis by creating a bacterial artificial chromo-
some (BAC) transgenic model that recapitulates the inv(3)(q21;q26) allele. Transgenicmice harboring a linked
BAC developed leukemia accompanied by EVI1 overexpression—neoplasia that was not detected in mice
bearing the same transgene but that was missing the GATA2 enhancer. These results establish the mecha-
nistic basis underlying the pathogenesis of a severe form of leukemia through aberrant expression of the EVI1
proto-oncogene.INTRODUCTION
Leukemias are often induced by the rearrangement of chromo-
somes through translocations or inversions (Mitelman et al.,
2007; Rowley, 2001). These chromosomal rearrangements can
result in two types of abnormalities. The majority result in coding
sequence fusions whereby a new protein is created. For
example, in chronicmyeloid leukemia, the t(9;22)(q34;q11) trans-
location creates a BCR-ABL fusion protein that functions as a
constitutively active form of ABL tyrosine kinase (Rowley,
1973). A minor form of proto-oncogene activation is inducedSignificance
Chromosomal rearrangements commonly create fusion onco
enhancer elements to proto-oncogenes, resulting in their mis
by translocation or inversion between 3q21 and 3q26 induces
In this study, we determined that a distant GATA2 hematopo
when inverted and that this enhancer is critical for AML neopl
that target regulatory regions that misdirect the activity of pro
anism for studying leukemias using transgenic BACs as a p
that result from chromosomal rearrangements.by linking the coding sequences of one gene to the regulatory se-
quences of a second gene, but approaches for exploring the
underlying mechanisms by which regulatory sequence changes
cause leukemias have proven to be technically challenging. One
example of the latter mechanism occurs when MYC (located
on 8q24) is placed under the regulatory control of the immuno-
globulin heavy chain (IGH) locus on 14q32, thus creating the
t(8;14)(q24;q32) translocation allele (ar-Rushdi et al., 1983).
In this regard, EVI1 is known to be a proto-oncogene that can
be activated by chromosomal translocation and inversion (Mor-
ishita et al., 1992), although the underlyingmechanisms that leadproteins but can also induce leukemia by linking foreign
expression. Misexpression of the human EVI1 gene caused
an acute myelogenous leukemia that has a poor prognosis.
ietic enhancer on 3q21 misdirects EVI1 expression on 3q26
asia. This finding suggests potential strategies for therapies
to-oncogenes. Additionally, this model establishes a mech-
owerful way to create and analyze various human cancers
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required for maintenance of hematopoietic stem cells (Goyama
et al., 2008), and overexpression of EVI1 has been observed in
high-risk myelodysplastic syndrome (MDS) and acute myeloid
leukemia (AML) (Lugthart et al., 2008). Indeed, EVI1 harbors
several hallmark functions that are normally associated with
leukemogenesis, with the following four possibly being the
most intriguing. First, EVI1 regulates the transcription of the tran-
scription factor genesGATA2 and PBX1, both of which play crit-
ical roles in the maintenance of hematopoietic stem cells, as well
as the tumor suppressor gene PTEN (Sato et al., 2008; Shimabe
et al., 2009; Yoshimi et al., 2011; Yuasa et al., 2005). Second,
EVI1 binds to the transcription factors RUNX1, PU.1, and
GATA1, thereby inhibiting their activity and blocking the differen-
tiation of hematopoietic progenitors (Laricchia-Robbio et al.,
2006, 2009; Senyuk et al., 2007). Third, EVI1 interacts with mul-
tiple epigenetic modification enzymes, each of which can alter
specific target gene expression profiles (Chi et al., 2003;
Goyama et al., 2010; Izutsu et al., 2001; Lugthart et al., 2011; Shi-
mahara et al., 2010; Spensberger et al., 2008; Yoshimi et al.,
2011). Fourth, forced EVI1 overexpression disrupts normal
centrosome duplication, creating increased genomic instability
(Stein et al., 2010).
It has been reported that both t(3;3)(q21;q26) and inv(3)(q21;
q26) chromosomal translocation and inversion between
3q21 and 3q26, respectively, cause inappropriate EVI1 gene
expression (Morishita et al., 1992; Suzukawa et al., 1994). In
both the translocated and inverted alleles, 3q21 has been
shown to always include sequences both 50 and 30 to the
EVI1 gene on 3q26. Because EVI1 is overexpressed in both
kinds of mutant alleles, we speculated that the 3q21 region
that is brought into close proximity to EVI1 as a result of
the translocation or inversion might harbor an enhancer that
then ectopically activates EVI1 gene expression. In this regard,
because all breakpoints on 3q21 are located downstream
of the ribophorin I (RPN1) gene, which encodes a transmem-
brane glycoprotein that is localized in the rough endo-
plasmic reticulum (Kreibich et al., 1978), we hypothesized
that one attractive possibility is that RPN1 enhancers might
provide the ectopic activation required for malignant EVI1
transcription.
The GATA2 gene is located 160 kb 30 to the RPN1 gene
on 3q21. GATA2 function is required in hematopoietic stem
cells, but its expression diminishes during hematopoietic differ-
entiation (Akashi et al., 2000; Lim et al., 2012; Minegishi
et al., 2003; Suzuki et al., 2006; Tsai and Orkin, 1997; Yama-
moto et al., 1990). In hematopoietic stem and progenitor
cells (HSPCs), GATA2 positively regulates the expression of
GATA2. Multiple phylogenetically conserved regions contain-
ing GATA factor binding sites reside in the mouse Gata2 locus
(at 3.9, 2.8, 1.8, and +9.5 kb from the Gata2 hematopoietic
and neuron-specific promoter I-specific [IS]), all of which bear
some degree of Gata2 enhancer activity (Grass et al., 2003,
2006; Johnson et al., 2012; Kobayashi-Osaki et al., 2005; Lim
et al., 2012; Snow et al., 2011). In addition to these promoter
and internal regulatory regions, another putative regulatory
element identified by Bresnick and colleagues is located
77 kb 50 to the Gata2 gene (Grass et al., 2006). This element
binds to GATA2 in the endogenous locus and acts as416 Cancer Cell 25, 415–427, April 14, 2014 ª2014 Elsevier Inc.an enhancer in transfection assays (Grass et al., 2006). This
element is located between RPN1 and the breakpoints that
occur in both the 3q21 and 3q26 translocations and inversions,
thus localizing this 77-kb 50 GATA2 site in close proximity to
the rearranged EVI1 gene in the resulting recombinant alleles.
We therefore hypothesized that the 77-kb GATA2 binding
sites might be in an enhancer that misdirects EVI1 transcription
in the translocated or inverted alleles between 3q21 and 3q26
and that this ectopic expression underlies the mechanisms
leading to leukemogenesis.
In this study, we asked whether the GATA2-bound sequences
located 77 kb from the Gata2 transcription start site indeed
function as enhancers in mouse HSPCs in vivo. We also linked
two bacterial artificial chromosomes (BACs) to generate a single
recombinant human BAC clone that recapitulates the juxtaposi-
tion of the sequences just as they are found in the inverted
human allele, then generated transgenic (Tg) mice harboring
this recombinant BAC to create a mouse model for leukemias
that are associated with chromosomal rearrangement.
RESULTS
Identification of a Gata2 Gene Distal Hematopoietic
Enhancer
The breakpoints in 3q21 AMLs all clustered within an approxi-
mately 25 kb region (Figure 1A, arrowheads in yellow region)
(Suzukawa et al., 1994, 1997). We found that a region ortholo-
gous to the mouse Gata2 gene 77-kb GATA sites is located
upstream (i.e., closer to RPN1) of the breakpoint cluster
(Figure 1A, blue circle). We first tested whether this region would
exhibit enhancer activity for Gata2 in HSPCs in vivo. To monitor
Gata2 gene expression in hematopoietic cells, we generated
GFP reporter Tg mouse lines using a BAC clone bearing
186 kb of 50 sequence flanking the Gata2 gene (G2BAC-GFP)
(Figure 1B). LoxP sites were then inserted on both sides of
the 77-kb GATA sites to test their contribution to GFP expres-
sion as a surrogate for Gata2. We injected the floxed BAC
(G2BAC-GFP-flox) DNA into fertilized ova and generated
G2BAC-GFP-flox Tg mice (Figure 1B). The G2BAC-GFP-flox
Tg mice were then crossed to Ayu1-Cre mice that express Cre
recombinase in their germline (Niwa et al., 1993) to generate lines
bearing the GATA binding-site-deleted BACs (G2BAC-GFP-
delta). Deletion of the element was confirmed by PCR (Figures
S1A and S1B available online).
In G2BAC-GFP-flox Tgmice, GFP fluorescence was intense in
a subset of LinSca-1+c-kit+ (LSK) and LinSca-1c-kit+ (LK)
progenitor cells, whereas little fluorescence was detected in
differentiated erythroid (TER-119+), B (B220+), or myeloid lineage
(Mac-1+) cells (Figure 1C, red lines). Thus, the BAC transgene
accurately recapitulates endogenous Gata2 gene expression in
hematopoietic cells (Akashi et al., 2000; Suzuki et al., 2003,
2006). Of note, in the G2BAC-GFP-delta Tg mice, the percent-
ages of GFP+ cells in both LSK and LK fractions were signifi-
cantly reduced compared to those in cells recovered from the
G2BAC-GFP-flox Tg mice (i.e., prior to deletion of the GATA
sequences) (Figure 1C, blue lines).
We further examined GFP fluorescence in long-term
hematopoietic stem cells (LT-HSCs) (CD34Flt3), short-
term hematopoietic stem cells (ST-HSC) (CD34+Flt3), and
Figure 1. Identification of the Gata2 Gene
Distal Hematopoietic Enhancer
(A) Schematic structure of human 3q21 region.
Arrowheads indicate documented breakpoints of
translocation and inversion between 3q21 and
3q26. The breakpoints clustered in an approxi-
mately 25-kb region (yellow region). A blue circle
indicates Gata2 distal hematopoietic enhancer
(G2DHE).
(B) Schematic structure of the G2BAC-GFP
transgenes. The mouse Gata2 locus is depicted
at the top. G2BAC-GFP transgenes (G2BAC-
GFP-flox or -delta) are shown beneath the
endogenous Gata2 locus. White triangles repre-
sent loxP sequences.
(C) Representative GFP histogram of bonemarrow
LSK, LK, TER-119+, B220+, and Mac-1+ cells from
G2BAC-GFP-flox (red lines) and G2BAC-GFP-
delta (blue lines) mice. The gray-shaded histo-
grams represent GFP fluorescence in wild-type
mice without a transgene [Tg ()].
(D) Representative GFP histogram in LT-HSCs,
ST-HSCs, MPPs, CMPs, GMPs, and MEPs
from G2BAC-GFP-flox (red lines) and G2BAC-
GFP-delta (blue lines) mice. The gray-shaded
histograms represent GFP fluorescence in Tg ()
mice.
(E) Percentages of GFP-positive cells in the indi-
cated fractions of G2BAC-GFP-flox (red bars) and
G2BAC-GFP-delta (blue bars) mice (n = 4). Data
are represented as mean ± SD. **p < 0.01
compared with G2BAC-GFP-flox mice.
See also Figure S1.
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GATA2 Enhancer-Directed EVI1-Dependent Leukemiamultipotent progenitors (MPPs) (CD34+Flt3+) in the LSK fraction
(Yang et al., 2005), as well as in common myeloid progenitors
(CMPs) (CD34+FcgRII/III3low), granulocyte/macrophage progen-
itors (GMPs) (CD34+FcgRII/III3high), andmegakaryocyte/erythro-
cyte progenitors (MEP) (CD34FcgRII/III3low) in the LK fraction
(Akashi et al., 2000). The fraction of GFP-positive cells was
significantly reduced at all stages in hematopoietic progenitors
in theG2BAC-GFP-delta Tgmice (Figures 1D and 1E). Therefore,
we refer to this sequence as the Gata2 distal hematopoietic
enhancer (G2DHE).
Gata2 is also expressed in nonhematopoietic cells, such as
neuronal, endothelial, and urogenital cells. As the G2BAC-GFP
Tg contains a neuronal enhancer, but not endothelial or urogen-
ital enhancers (Khandekar et al., 2004, 2007), the G2BAC-GFP
Tg recapitulates Gata2 expression only in neural tissues, espe-
cially in the midbrain (Nozawa et al., 2009). Therefore, we exam-
ined the contribution of G2DHE to Gata2 expression in the
midbrain and found that GFP fluorescence and mRNA levels in
the midbrains of the G2BAC-GFP-delta Tg mice were compara-
ble to those in the G2BAC-GFP-flox Tg mice (Figures S1C–S1E).
These results indicate that G2DHE is dispensable forGata2 gene
expression in the midbrain.
Generation of 3q21q26 Tg Mice by Linking Two BACs
To determine whether G2DHE activates EVI1 transcription
in the rearranged allele, we generated a Tg model mouseline that would precisely recapitulate the breakpoints in
inv(3)(q21;q26). To do so, we duplicated the specific inversion
breakpoint in the MOLM-1 cell line, which was originally es-
tablished from a patient with megakaryoblastic leukemia
bearing the inv(3)(q21;q26) inversion (Matsuo et al., 1991;
Suzukawa et al., 1997). In MOLM-1 cells, inversion occurred
between the 3rd exon of the C3ORF27 gene in 3q21 and the
15th intron of EVI1 in 3q26 (Suzukawa et al., 1997). As the
position of the precise breakpoint has not been reported, we
determined the sequence of the MOLM-1 inversion breakpoint
(Figure 2A).
We next generated a BAC clone harboring recombinant
human DNA that precisely recapitulated the inv(3)(q21;q26)
genomic region in MOLM-1 cells by linking two BAC clones
(RP11-662G11 and RP11-94J18) containing the 3q21 and
3q26 sequences, respectively (Figure 2B) (Brandt et al., 2008).
During the process of BAC modification, we found both a
full-length (indicated by an asterisk) and a partially deleted
RP11-662G11 clone (Figure 2C, arrowhead; hereafter RP11-
662G11d). Closer analysis revealed that the recombinant insert
of the deleted clone lacked approximately 50 kb of flanking
sequences 50 to the RPN1 gene (data not shown). We therefore
chose to use this deleted clone in subsequent studies, thus
allowing us to exclude any possible contribution of RPN1
expression to EVI1 transcription. We targeted loxP514 se-
quences into the breakpoint positions of the RP11-662G11dCancer Cell 25, 415–427, April 14, 2014 ª2014 Elsevier Inc. 417
Figure 2. Generation of 3q21q26 Mice by Linking Two BACs
(A) Chromosomal inversion of the region between breakpoints (yellow arrowheads) in EVI1 (brown box) and C3ORF27 (orange box) genes in MOLM-1 cells. The
boxed sequence shows the breakpoint between 3q21 (red) and 3q26 (black).
(B) Strategy for linking two BAC clones. Human BACs RP11-94J18 (94J18) and RP11-662G11 (662G11) contain 3q26 and 3q21, respectively. We used site-
specific Cre-mediated recombination to link the two BAC clones by simultaneous intermolecular homologous recombination between the loxP514 (black
triangles) and loxP511 (white triangles) sites. Neo, Cm, and Amp indicate the neomycin-, chloramphenicol-, and ampicillin-resistant genes, respectively.
(C) Pulse-field gel electrophoresis of BAC clones. We found two types of 662G11 clones: full-length (asterisk) and partially deleted (arrowhead).
(D) Schematic representations of the inverted allele, 3q21, 3q26, 3q21q26, and 3q21q26DG2DHE BAC transgenes. Red and black lines represent contributions
from 3q21 and 3q26, respectively.
(E) Copy numbers of integrated transgenes. Copy numbers were determined by qPCR using Tg (), 3q26 (lines A and B), 3q21q26 (lines A, B, and C), and
3q21q26DG2DHE (lines A and B) mice (n = 3–6). Red numbers depicted above the bar graphs represent copy numbers of transgenes.
See also Figure S2, Table S1, and Supplemental Information.
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subsequently linked these two BAC clones by simultaneous
Cre-mediated recombination between the loxP514 sites inserted
at the breakpoints and between the loxP511 sites in the BAC
vector backbones. The linked BAC clone was named 3q21q26.
We verified that the 3q21q26 clone contained the 64-kb region
of 3q21 and the expected 132-kb region of 3q26 by pulse-field
gel electrophoresis, Southern blotting, and fingerprinting (Fig-
ure 2C; Figures S2C–S2G).
Utilizing the 3q21q26 clone, we generated three lines of Tg
mice (3q21q26 mice) (Figure 2D). For one negative control, we
also generated two lines of Tg mice harboring the unlinked
3q26 BAC clone (3q26 mice). To directly test whether the
G2DHE could activate EVI1 in the inverted allele, we also deleted
the G2DHE from 3q21q26 (referred to as 3q21q26DG2DHE) and
generated two additional lines of Tg mice (Figure 2D; Figures
S2H–S2J). All of the 3q21q26, 3q26, and 3q21q26DG2DHE Tg
mice were born in the expectedMendelian ratios, grew normally,
and were fertile (Table S1). The copy numbers for the integrated
transgenes was determined by quantitative PCR (qPCR), which
revealed that the mice retained from two to six copies of the
transgenes (Figure 2E).418 Cancer Cell 25, 415–427, April 14, 2014 ª2014 Elsevier Inc.Expression of the Human EVI1 Transgene in HSPCs of
3q21q26 Mice
Whereas only hematopoietic lineage cells harbor the rearranged
allele in human patients, every cell type should share the rear-
ranged allele in the 3q21q26 mice. Therefore, it was important
to determine the expression profile of the human EVI1 transgene
in the 3q21q26 mice. We quantified EVI1 expression levels using
three primer pairs that detected exclusively either the human
transgene EVI1 or the endogenous murine Evi1 gene or detected
both simultaneously. Interestingly, the human EVI1 transgene
was specifically expressed in hematopoietic tissues (spleen
and thymus) in the 3q21q26 mice (Figure 3A), whereas the
endogenous Evi1 gene was also highly expressed in the lung
and kidney (Figure 3B). In these mice, the abundance of human
EVI1mRNA in hematopoietic tissues is comparable to that of the
mouse Evi1 mRNA in the lung and kidney (Figure 3C). These re-
sults are consistent with the notion that the human 3q21q26
transgene bears enhancer activity that can activate EVI1 in
hematopoietic tissues.
To more precisely examine the expression profiles of the
EVI1 transgene in hematopoietic lineages, bone marrow
cells were fractionated into stem cells, progenitors, or various
Figure 3. Expression Profiles of the Human EVI1 Transgene in 3q21q26 Mice
(A–C) Expression levels of EVI1 gene in hematopoietic and nonhematopoietic tissues. Expression levels of human EVI1 mRNA (A), mouse endogenous Evi1
mRNA (B), and total (human +mouse)EVI1mRNA (C) in hematopoietic tissues (spleen and thymus) and nonhematopoietic tissues (lung, kidney, liver, and brain) of
Tg () controls (n = 10), 3q21q26mouse lines (line A, n = 3; line B, n = 3; line C, n = 3), and 3q21q26DG2DHE line B (n = 4) were determined. The level of eachmRNA
was normalized to rRNA abundance. In panels (B) and (C), average values for Tg () spleen cells were set to 1, and in panel (A) spleen cells of 3q21q26 line A
were set to 1.
(D and E) Abundance of EVI1 gene expression in hematopoietic cells. Expression levels of human EVI1mRNA (D) and total EVI1mRNA (E) in hematopoietic stem
and progenitor cells and differentiated cells in Tg () (n = 19), 3q21q26 (line A, n = 3–6; line B, n = 3–7; line C, n = 4), and 3q21q26DG2DHE line B (n = 4) bone
marrowwere determined. The abundance of eachmRNAwas normalized to the rRNA abundance. Average values for 3q21q26 line A LSK cells (D) and Tg () LSK
cells (E) were set to 1.
Bar graph data are represented as mean ± SD. Arrows indicate undetectable expression levels. *p < 0.05; **p < 0.01 compared with Tg () controls. #p < 0.05;
##p < 0.01 compared between two indicated groups.
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pressed in the LSK fraction, which contains HSPCs, but its
expression diminished upon differentiation (Figures 3D and
3E). This expression pattern of the rearranged EVI1 transgene re-
capitulates that of the endogenous Gata2 gene (Minegishi et al.,
2003; Suzuki et al., 2006; Tsai and Orkin, 1997) and is similar to
that of the endogenous (murine) Evi1 gene in hematopoietic cells
(Kataoka et al., 2011). The abundance of EVI1mRNAwas depen-
dent on the copy number of the integrated transgenes in LSK and
LK fractions of the 3q21q26 mice (Figure 3E).
In the 3q21q26DG2DHE mice, expression of EVI1 transgene
was also detected in hematopoietic tissues (Figures 3A–3C).
Of note, we found that, whenmice harbor the same copy number
of transgenes, the total EVI1 mRNA level is clearly diminished in
LSK and LK fractions of the 3q21q26DG2DHEmice compared to
those of the 3q21q26 mice (Figure 3E). These results indicate
that G2DHE contributes to elevated EVI1 gene expression in
hematopoietic cells.
3q21q26 Mice Develop G2DHE-Dependent Leukemia
To determine whether the 3q21q26 mice develop leukemia,
we examined a cohort of these animals, and determinedby Kaplan-Meier analyses that the 3q21q26 mice survived
far shorter than control [(Tg ()] or 3q26 mice (Figure 4A). All
three lines (lines A, B, and C) of 3q21q26 mice exhibited
similar survival durations and began to die 200 days after
birth (Figure 4A, inset graph). Hematological indices of the
3q21q26 mice revealed that white blood cell numbers in the
peripheral blood increased markedly after 24 weeks (Figure 4B)
with constitutive mild anemia (Figure 4C). 3q21q26 mice
that had increased (>5 3 104/ml) white blood cell counts were
analyzed (Figures 4D and 4E) and found to display marked
splenomegaly (Figures 4F and 4G). Leukocytes had infiltrated
into the liver, lung, heart, and kidney in the 3q21q26 mice
(Figure 4H), suggesting that the 3q21q26 mice developed
leukemia.
When we carried out cohort studies of the 3q21q26DG2DHE
mice to determine whether G2DHE contributed to leukemo-
genesis, we determined that 3q21q26DG2DHE mice survived
similarly to control [Tg ()] mice and did not develop leukemia
over the 400-day time course of the experiment (Figure 4A).
These results firmly support the contention that G2DHE is
essential for EVI1-dependent leukemogenesis in the 3q21q26
mice.Cancer Cell 25, 415–427, April 14, 2014 ª2014 Elsevier Inc. 419
Figure 4. 3q21q26 Mice Develop G2DHE-
Dependent Leukemia
(A) Kaplan-Meier survival curve of Tg () (n = 96),
3q26 (n = 55), 3q21q26 (n = 121), and
3q21q26DG2DHE (n = 26) mice. Survival rates
were calculated by compiling data from multiple
Tg mouse lines. The inset graph shows the overall
survival of each line of 3q21q26 mice (lines A,
B, and C).
(B and C) White blood cell counts (B) and hemat-
ocrit levels (C) in the peripheral blood of Tg ()
(n = 11–46) and 3q21q26 line A (n = 6–19), line B
(n = 5–15), and line C (n = 3–9) mice.
(D) Representative smears of peripheral blood
taken from Tg () and leukemic 3q21q26 mice.
Scale bar, 20 mm.
(E) The numbers of white blood cells in leukemic
3q21q26 line A (n = 6), line B (n = 7), and line C
(n = 3) mice and their Tg () (n = 5) littermates.
(F) Representative spleens from Tg () and
leukemic 3q21q26 mice. Scale bar, 1 cm.
(G) Average spleen weights from Tg () (n = 5) and
leukemic 3q21q26 line A (n = 6), line B (n = 7), and
line C (n = 3) mice.
(H) Hematoxylin-eosin staining of tissues of Tg ()
(top panels) and leukemic 3q21q26 line B (bottom
panels) mice. Scale bar, 100 mm.
Bar graph data are represented as mean ± SD.
*p < 0.05; **p < 0.01 compared to Tg () controls.
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In human chromosomal rearrangements between 3q21 and
3q26, EVI1 ectopic expression results primarily in myeloid rather
than lymphoid leukemia (Lugthart et al., 2008). To determine
whether leukemia in the 3q21q26 mice recapitulates the human
leukemia most often associated with EVI1 misexpression, we
analyzed the peripheral blood and bone marrow of the
3q21q26 mice. In all three lines of the 3q21q26 mice, CD34+
and c-kit+ blast cells were observed in the peripheral blood (Fig-
ure 5A), whereas blast cells were only rarely observed in Tg ()
mice. CD34+ and c-kit+ cells were also more frequent in the
bone marrow of 3q21q26 mice (Figure S3A). Additionally,
B220+ antigenwas detected in the 3q21q26 line Amice, whereas
Gr-1+ andMac-1+ antigens were detected in the 3q21q26 lines B
and C mice (Figure 5A; Figure S3A).
When different combinations of surface markers were
analyzed, three distinct types of leukemia could be discerned
in the 3q21q26 mice. The first is a B-cell type in which B220+
cells had preferentially expanded (Figure 5B, left panel). The sec-
ond is a GM type in which Gr-1+Mac-1+ cells had abundantly420 Cancer Cell 25, 415–427, April 14, 2014 ª2014 Elsevier Inc.expanded (Figure 5B, right panel). Inter-
estingly, the third type is one in
which both B220+ and Gr-1+Mac-1+ had
increased (Figure 5B, center panel).
Morphological analyses of the peripheral
blood showed that lymphoid cells, neu-
trophils, or both were expanded in the
B, GM, and B+GM types of leukemia,
respectively (Figure 5C). In the B- and
B+GM-type leukemias, B220+ cells ex-
pressed c-kit and Flt3, but not CD19(Figures S3B and S3C), indicating that these cells correspond
to pre-pro-B cells (Nutt and Kee, 2007).
We note that the incidence of each type of leukemia correlated
with increased copy numbers of the integrated transgenes.
3q21q26 line A mice bear two copies of the transgene and
developed B-cell leukemia, whereas GM-type leukemias were
observed in 3q21q26 mouse lines B and C, which bore three
or four copies of the transgene, respectively (Figure 5D). These
results, taken together, suggest that the 3q21q26 mice, espe-
cially mice of lines B and C that express more abundant human
EVI1, most accurately recapitulate the phenotype and patho-
physiology of human leukemia that is accompanied by EVI1
ectopic expression.
3q21q26 Leukemic Cells Expand Autonomously
To determine whether the leukemic cells developed in the
3q21q26 mice progress autonomously if supported by wild-
type cells in the leukemic niche, we isolated bone marrow cells
from the 3q21q26 mice and transplanted them into nude mice.
All recipient nude mice died with latencies of approximately
Figure 5. 3q21q26 Mice with Three Types of Leukemia
(A) Expression profiles of CD34, c-kit, B220, CD3a, Gr-1, Mac-1, and TER-119 in peripheral blood (PB) leukemic cells of 3q21q26 line A (n = 5), line B (n = 5–6), and
line C (n = 3) mice, as well as mononuclear cells of Tg () mice (n = 4–5). *p < 0.05; **p < 0.01.
(B) Flow cytometric analysis of leukemic cells in 3q21q26 mice. Representative flow cytometric patterns of B-type (left panel), B+GM-type (middle panel), and
GM-type (right panel) leukemias are shown.
(C) Wright-Giemsa staining of leukemic cells in the peripheral blood of 3q21q26 mice. Scale bar, 10 mm. As a control, mononuclear cells from Tg () mice are
shown.
(D) Frequencies of B-type (white), B+GM-type (gray), and GM-type (black) leukemia developed in the three 3q21q26 mouse lines.
See also Figure S3.
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mice, the recipient nude mice exhibited marked splenomegaly
(Figure 6B). In the peripheral blood of the recipients, the number
of white blood cells dramatically increased over time, whereas
red blood cells and platelets both diminished, indicating that
the recipient mice developed transplant-dependent leukemia
(Figures 6C–6E).
We next carried out flow cytometry and morphological anal-
ysis of leukocytes in the peripheral blood and examined whether
the phenotypes of the leukemia that developed in the recipientnude mice recapitulated that of the donors. All recipient nude
mice developed leukemias (Figures 6F and 6G). In perfect agree-
ment with analyses of the various donor animals, leukemic cells
in the recipient mice developed B-, GM-, or B+GM-type leuke-
mias in lines A, B, and C and exhibited identical morphologies
in lymphoid and/or neutrophil populations (Figure 6H). These
data demonstrate that leukemic cells from the 3q21q26 mice
progress autonomously in the transplanted nude mice, indi-
cating that the leukemic cells in primary mice do not require a
mutant microenvironment for their propagation.Cancer Cell 25, 415–427, April 14, 2014 ª2014 Elsevier Inc. 421
Figure 6. Leukemic Cells of 3q21q26 Mice Expand Autonomously
(A) Kaplan-Meier survival curve of recipient nude mice (n = 12) transplanted with 107 mononuclear bone marrow cells from leukemic 3q21q26 mice.
(B) Representative spleens from control or recipient nude mice 40 days after transplant. Scale bar, 1 cm.
(C–E) Numbers of white blood cells (C), red blood cells (D), and platelets (E) in peripheral blood in control (n = 3) and transplanted (n = 11) nude mice. **p < 0.01
compared with control nude mice.
(F) Representative flow cytometric analyses of peripheral blood cells from donormice with B-, B+GM-, and GM-type leukemia and comparison to their respective
recipient nude mice.
(G) Leukemia types of donor and recipient mice. Numbers in the table represent the number of mice with each type of leukemia.
(H) Wright-Giemsa staining of leukemic cells in the peripheral blood of transplant recipient nude mice with B-, B+GM-, and GM-type leukemia. Scale bar, 10 mm.
Bar graphs are represented as mean ± SD.
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Cell Population in 3q21q26 Mice
As thehumanEVI1 transgenewashighlyexpressed inLSKcellsof
the 3q21q26 mice, we hypothesized that misexpression of EVI1
in Tg HSPCs might have contributed to the leukemogenesis. To
address this hypothesis, we quantified the absolute number of
HSPCs in the bone marrow of 12-week-old 3q21q26, 3q26, and
3q21q26DG2DHE mice prior to the onset of frank leukemia.
Bone marrow cellularity in the 3q21q26 mice was comparable
to that in the 3q26 mice, whereas the number of LSK cells
increased in the 3q21q26 mice (Figures 7A and 7B). Of specific
note, the number of LSK cells in 3q21q26DG2DHE mice was
much lower than that in 3q21q26 mice.
We fractionated the LSK fraction of the 3q21q26 mice into LT-
HSC, ST-HSC, and MPP as usual and discovered an abnormal
CD34highFlt3 cell fraction. The CD34highFlt3 cells accumulated
abundantly in LSK cells of the 3q21q26 mice, but not in 3q26
animals or in the LSK faction of control Tg () mice (Figures 7C
and 7D). The CD34highFlt3 cells were still observed in
3q21q26 mice with myeloid leukemia, suggesting that these
cells are associated with myeloid leukemia (Figures S4A and
S4B). We next examined the LK fractions containing CMP,
MEP, and GMP cells and found that the number of CMP cells
was fewer in 3q21q26 mice than in 3q26 or control [Tg ()]422 Cancer Cell 25, 415–427, April 14, 2014 ª2014 Elsevier Inc.mice, indicating that differentiation of the CMP cells was defi-
cient in the 3q21q26 mice (Figures 7E and 7F). The phenotypic
accumulation of CD34highFlt3 cells was partially reversed in
the LSK cells of 3q21q26DG2DHE mice, indicating that the dif-
ferentiation defects observed in the 3q21q26 progenitor cells
were rescued, at least in part, by deletion of theGATA2 enhancer
from the linked BAC (Figures 7C and 7D).
G2DHE Drives EVI1 Overexpression in HSPCs
To elucidate whether the 3q21 region, and specifically G2DHE,
is able to direct ectopic EVI1 gene expression in HSPCs, we
examined EVI1 transcription. The abundance of human EVI1
mRNA was significantly elevated in LT-HSCs, ST-HSCs, and
MPPs from the 3q21q26 mice in comparison to 3q26 mice (Fig-
ure 7G). In contrast, human EVI1 abundance in the CD34highFlt3
fraction was much lower than in the LT-HSCs, ST-HSCs,
and MPPs fractions. Overexpression of the human EVI1 trans-
gene was significantly diminished in the enhancer-deleted
3q21q26DG2DHE mice, demonstrating that G2DHE could be
directly responsible for activating the human EVI1 transgene in
LT-HSCs, ST-HSCs, and MPPs. Unexpectedly, we found that
the levels of endogenousmouse Evi1mRNA diminished to unde-
tectable levels in the 3q21q26 and the 3q21q26DG2DHE mice
(Figure 7H). The total EVI1 level (human EVI1 + mouse Evi1
Figure 7. G2DHE Drives EVI1 Overexpression in HSPCs
(A–F) Representative flow cytometric profiles of Lin cells (A), LSK cells (C), and LK cells (E) in 12-week-old Tg (), 3q26 line B, 3q21q26 line B, and
3q21q26DG2DHE line Bmice. Analysis of cells in red boxes is shown in panels (B), (D), and (F). Absolute cell numbers of LSK and LK cells (B), LT-HSCs, ST-HSCs,
MPPs, and CD34highFlt3 (CD34high) cells (D), and CMPs, MEPs and GMPs (F) in the Lin cell population in 12-week-old Tg () (white, n = 4), 3q26 line B (blue,
n = 4), 3q21q26 line B (pink, n = 4), and 3q21q26DG2DHE line B (green, n = 4) mice are depicted.
(G–I) Expression levels of human EVI1mRNA (G), mouse endogenous Evi1mRNA (H), and total EVI1mRNA (I) in LT-HSC, ST-HSC, MPP, CD34high, CMP, MEP,
and GMP fractions in 12-week-old Tg () (white, n = 4–8), 3q26 line B (blue, n = 4–8), 3q21q26 line B (pink, n = 4–8), and 3q21q26DG2DHE line B (green, n = 4–8)
mice. The expression level of each mRNA was normalized to rRNA abundance. Average values for 3q26 LT-HSC cells (G) and Tg () LT-HSC cells (H and I)
were set to 1.
Bar graph data are represented as mean ± SD. Arrows indicate undetectable levels. N.D., not determined. *p < 0.05; **p < 0.01 compared with Tg () controls.
#p < 0.05; ##p < 0.01 compared between two indicated groups.
See also Figure S4.
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GATA2 Enhancer-Directed EVI1-Dependent LeukemiamRNAs) in the 3q21q26 mice was higher than in the 3q26 mice,
but the level in the 3q21q26DG2DHE mice was comparable
to that in the 3q26 mice (Figure 7I). These results indicate
that the G2DHE located in the 3q21 region activates EVI1transcription in the inverted 3q26 allele, leading to the observed
leukemogenesis.
In LT-HSCs of 3q21q26 mice, the levels of known EVI1 target
genes Gata2 and Pbx1 mRNAs (Shimabe et al., 2009; YuasaCancer Cell 25, 415–427, April 14, 2014 ª2014 Elsevier Inc. 423
Figure 8. A Model for the Involvement of G2DHE in Normal and
3q21q26 Inverted/Translocated Hematopoietic Cells
In normal hematopoietic progenitors, G2DHE enhances GATA2 transcription
(top panel). In AML, G2DHE becomes localized downstream or upstream of
the EVI1 gene in inv(3)(q21;q26) (middle panel) or t(3;3)(q21;q26) (bottom
panel) alleles, respectively. In both cases, the chromosomal rearrangement-
dependent juxtaposition of G2DHE induces EVI1 gene transcription instead of
GATA2 transcription, which subsequently leads to leukemia.
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GATA2 Enhancer-Directed EVI1-Dependent Leukemiaet al., 2005), but not Myb, Foxo3a, and Meis1, were increased
compared with Tg () mice (Figure S4C). These results indicate
that EVI1 upregulates a subset of target genes, which are impor-
tant for the maintenance of HSCs, in LT-HSCs of the 3q21q26
mice. Additionally, the abundance of Pten tumor suppressor
(Yoshimi et al., 2011) and the cyclin-dependent kinase inhibitor
p57 (Matsumoto et al., 2011) was lower in 3q21q26 LT-HSCs.
We envisage that EVI1 may provoke the progression of the
cell cycle by regulating Pten and p57 expression. In the
CD34highFlt3 cells from the 3q21q26 mice, the abundance of
Meis1, Gata2, Pbx1, and p57 gene transcripts, which are all
highly expressed in LT-HSCs, had largely decreased; in contrast,
we detected high levels of PU.1. These results collectively sug-
gest that the CD34highFlt3 cells retain gene expression profiles
similar to myeloid progenitor cells rather than stem cells.
DISCUSSION
Translocation or inversion between 3q21 and 3q26 induces
aberrant EVI1 gene expression, giving rise to human AML, which424 Cancer Cell 25, 415–427, April 14, 2014 ª2014 Elsevier Inc.carries a poor prognosis. In this paper, we describe the contribu-
tion of a far upstream hematopoietic enhancer of the GATA2
gene (G2DHE) to EVI1 gene expression in a typically rearranged
human inversion. We generated 3q21q26 mice by linking two
separate BAC clones containing the 3q21 and 3q26 regions in
the same physical orientation as they are found in a common
AML cell line and found that the Tg mice developed leukemias
only when EVI1 was ectopically activated by G2DHE when the
two genetic elements were brought into close proximity as a
consequence of the inversion. We propose a model for EVI1-
misexpressed leukemia that is associated with chromosomal
rearrangements (Figure 8). In normal hematopoietic cells, the
G2DHE is at least partially responsible for activating GATA2
gene expression (Figure 8, top panel). In leukemia cells bearing
inversions or translocations between 3q21 and 3q26, G2DHE
becomes localized either 30 or 50 to the EVI1 gene, respectively
(Figure 8, middle and bottom panels). G2DHE activates the
EVI1 gene instead ofGATA2 in HSPCs, thereby leading to leuke-
mogenesis. This model is further supported by the conclusions
from a study employing a completely different approach exam-
ining leukemic cells from human patients bearing the rearranged
allele (Gro¨schel et al., 2014).
G2DHE was originally identified as a phylogenetically con-
served region containing binding sites for transcription factors
GATA1 and GATA2 in the mouse Gata2 locus (Grass et al.,
2006). It has been shown that theGata2 gene regulation is highly
dependent on these GATA factors. The Gata2 gene is activated
by GATA2 itself in HSPCs, but becomes repressed by GATA1 as
progenitors differentiate into erythroid cells (Grass et al., 2003,
2006; Kobayashi-Osaki et al., 2005; Snow et al., 2010). GATA2
and GATA1 bind to several sites in the Gata2 locus, including
three sites in G2DHE. We assume that GATA2 and GATA1 differ-
entially bind to these motifs in a differentiation-dependent
manner as erythroid progenitors switch from proliferation to ter-
minal differentiation (Bresnick et al., 2010; Kaneko et al., 2010;
Suzuki et al., 2011, 2013). Similarly, we surmise that EVI1 gene
activation by G2DHE occurs in a manner that is dependent on
these GATA factors. Additionally, a number of transcription fac-
tors, such as GFI1, SCL, MEIS1, RUNX1, ERG, LMO2, and FLI1
bind to G2DHE in human hematopoietic cell lines (Moignard
et al., 2013). Therefore, identification of the mechanisms that
regulate EVI1 gene expression though G2DHE is a critical future
objective for identifying potential therapeutic targets for EVI1
expression-based leukemia.
Several mouse models for EVI1-expressing leukemia have
been reported (Buonamici et al., 2004; Louz et al., 2000; Yoshimi
et al., 2011). In particular, Yoshimi et al. established a mouse
model by transplanting bone marrow cells in which EVI1 was
introduced using a retrovirus (Yoshimi et al., 2011). Of these
experimental leukemia models, the present approach is
different, because in the 3q21q26 mice, (1) the expression level
of EVI1 is evenly controlled by being borne in a BAC, (2) the
expression profile of EVI1 is defined by human 3q21 locus and
is highly reproducible, and (3) the timing of EVI1 expression reca-
pitulates that of the human leukemia cases bearing chromosome
rearrangements. However, the leukemias that develop in the
3q21q26 mouse model appear to be similar to those utilizing
retroviral infection of EVI1 in mice, in which the EVI1 gene is ex-
pressed in hematopoietic cells. Both models develop leukemia
Cancer Cell
GATA2 Enhancer-Directed EVI1-Dependent Leukemiawith long latency (more than 6 months), and both models
develop both myeloid and B-cell leukemia. Nonetheless, these
observations further support the contention that the leukemo-
genesis in the 3q21q26 mice is caused by dysregulated EVI1
expression in hematopoietic cells; however, we need further ex-
periments to exclude decisively the possibility that a mutant
microenvironment is necessary for de novo development of the
leukemia in the 3q21q26 mice.
It is still unknown how the EVI1 misexpression induces B-cell
leukemia in addition to myeloid leukemia. In this regard, it should
be noted that the 3q21q26 cellular analysis clearly revealed that
both types of leukemia correlate with EVI1 expression levels.
EVI1 overexpression has also been observed in pediatric acute
lymphoblastic leukemia (ALL) (Konantz et al., 2013). In very
good agreement with these observations in the 3q21q26 mouse
model, the EVI1 level in pediatric ALL patients is lower than that
in AML, and EVI1 levels in ALL patients has been shown to corre-
late with disease prognosis (Konantz et al., 2013).
Whereas the EVI1 gene expression level diminishes signifi-
cantly in the GATA2 enhancer-deleted BAC Tg mice and the
mice no longer develop leukemia, theEVI1 gene is still expressed
to a certain extent in the enhancer-deleted mouse bone marrow
cells. We do not have a salient explanation for this observation at
present, but the following points may be relevant. One plausible
explanation is that EVI1 may be activated in only a minor subset
of cells in the LSK fraction of 3q21q26 mice, and it is these cells
that play a critical role in the leukemogenesis. As EVI1 is an
essential transcription factor for normal hematopoietic stem
cell maintenance (Goyama et al., 2008), it may play equally
important roles in the maintenance of leukemic stem cells. Moni-
toring EVI1 expression at the single-cell level using novel Tgmice
in which a reporter is expressed under the control of the 3q21q26
BAC would be valuable to investigate this possibility.
An alternative explanation is that there may be a strict
threshold requirement for EVI1-dependent leukemogenesis
and that impaired activation of EVI1 in the 3q21q26DG2DHE
mice may be insufficient to surmount that threshold. The
threshold model has already been proposed for the onset of leu-
kemia that depends on the gene dosage of transcription factor
PU.1 (Rosenbauer et al., 2004; Steidl et al., 2006). Deletion of
the upstream regulatory element of the Sfpi1 gene encoding
PU.1 gives rise to an 80% reduction in the levels of PU.1
comparedwith its normal abundance, which specifically induced
leukemia. Meanwhile, complete or even a 50% reduction in PU.1
did not induce leukemia, indicating that sensitive fine-tuning of
transcription factor levels by specific enhancers may be critical
for the suppression of leukemogenesis.
We believe that this Tg mouse model approach, exploiting the
BAC-linking technique, is equally applicable to the analysis of
other leukemias or diseases that are associated with chromo-
somal rearrangements. Especially by applying BAC clones
from human genomic libraries to Tg mouse studies, we can
generate very precise mouse models of human rearranged
alleles. The BAC-linking method enables us to generate rear-
ranged alleles with any combination of alleles or breakpoints,
and the technique of Tg mouse generation combined with the
BAC-linking method is relatively straightforward to manipulate.
Therefore, this approach using linked BACs in Tg mice should
prove to be useful in providing vivid insights into the mechanisticbasis for the pathogenesis of various leukemias that are caused
by chromosomal rearrangements.
EXPERIMENTAL PROCEDURES
Mice
Generation of Tg mice using BAC recombination is described in the Supple-
mental Information. All mice were handled according to the regulations of
the Standards for Human Care and Use of Laboratory Animals of Tohoku
University and the Guidelines for Proper Conduct of Animal Experiments of
the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
Hematological Analysis
Peripheral blood (30–50 ml) was collected from individual mice. Hematopoietic
indices were determined using a hemocytometer (Nihon Kohden). Hemogram
profiles were examined byWright-Giemsa staining. Flow cytometric analysis is
described in the Supplemental Information.
Histological Analysis
Each organ was fixed with 10% formalin (Mildform 10N;Wako) and embedded
in paraffin using standard procedures. Sections (5 mm) were stained with
hematoxylin-eosin.
Quantitative RT-PCR
Gene expression levels were determined by qRT-PCR as described in the
Supplemental Information.
Statistical Analysis
The statistical significance of differences between parameters was assessed
using a two-tailed, unpaired Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2014.02.008.
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